Quick navigation menu :

  1. Go to main section's menu
  2. Go to Search tool
  3. Go to Help menu
  4. Go to modules
  5. Go to the list of keyboard shortcuts

Help menu :

  1. Sanofi Worlwide |
     
  2. Global Business Websites |
     
  3. Contact Us |
  4. Sitemap |
  5. Help
  1. Font size

    Reduce Increase  
 
 

Metabolic Disorders

Contact

Sanofi Bangladesh Limited

6/2/A Segun Bagicha
Dhaka 1000
Bangladesh

Tel. : +880 96 78 000 777
Fax : +880 2 955 0009

Content :

Metabolic Disorders

Metabolic Disorders

Diabetes mellitus is a common condition where there is too much of the sugar called glucose in the blood, because the body is unable to convert it into energy in the normal way. There are approximately 5 million population who is suffering from diabetes in Bangladesh. In almost all cases, this is because not enough insulin is produced by the body. Diabetes mellitus (DM) is the most common metabolic condition affecting the world population.

 

Amaryl once daily tablet, launched in 2001, is the 3rd generation sulphonylurea for treatment of Type-2 diabetes. The other oral product available is Daonil.

Insuman, launched in 2003, is Recombinant DNA Human Insulin and is available in 5 ml vials with all three preparations i.e. Insuman Rapid, Insuman Basal and Insuman Comb (pre-mixed).

Lantus, the latest addition in the portfolio, is the peak-less once daily basal insulin analogue and was launched in 2005.

Sanofi also have other diabetic and metabolic products planned for the future.

Updated January 23, 2007